ArticleRadiology2020
Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
Article in Radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Super-Resolution MR Spectroscopic Imaging via Diffusion Models for Tumor Metabolism Mapping.Journal of imaging informatics in medicine · 2026Article
- Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Neuro-oncology · 2026Review
- Imaging-mediated genetic effects link brain microstructure, metabolic profiles, and regional transcription to glioma susceptibility.Frontiers in immunology · 2026Article
- A biopsy-validated study of combined DL-upscaled MRSI and (18F)-FACBC PET for presurgical glioma diagnosis.Frontiers in oncology · 2026Article
- Accelerated Navigator for Rapid ∆BNMR in biomedicine · 2025Article
- Elevated glioma-related cortical glutamateBrain communications · 2025Article
- Advanced imaging techniques and non-invasive biomarkers in pediatric brain tumors: state of the art.Neuroradiology · 2024Review
- Multimodal MRI andDiagnostics (Basel, Switzerland) · 2024Article
- ECCENTRIC: A fast and unrestrained approach for high-resolution in vivo metabolic imaging at ultra-high field MR.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Article
- The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.Journal of neuro-oncology · 2024Article
- Review
- In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic Imaging.Journal of magnetic resonance imaging : JMRI · 2022Article
- Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/BNMR in biomedicine · 2022Article
- Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism.Frontiers in neurology · 2022Review
- Saturation Transfer MRI for Detection of Metabolic and Microstructural Impairments Underlying Neurodegeneration in Alzheimer's Disease.Brain sciences · 2021Review
- Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.Current oncology reports · 2021Review
- Unsupervised learning of metabolic fingerprints from 3D magnetic resonance spectroscopic imaging enables glioma subtype classification.Neuro-oncology advancesArticle
- Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma.Neuro-oncology advancesArticle
- Accurate prediction of isocitrate dehydrogenase -mutation status of gliomas using SLOW-editing magnetic resonance spectroscopic imaging at 7 T MR.Neuro-oncology advancesArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Background Isocitrate dehydrogenase (IDH) mutations are highly frequent in glioma, producing high levels of the oncometabolite D-2-hydroxyglutarate (D-2HG). Hence, D-2HG represents a valuable imaging marker for IDH-mutated human glioma. Purpose To develop and evaluate a super-resolution three-dimensional (3D) MR spectroscopic imaging strategy to map D-2HG and tumor metabolism in IDH-mutated human glioma. Materials and Methods Between March and September 2018, participants with IDH1-mutated gliomas and healthy participants were prospectively scanned with a 3-T whole-brain 3D MR spectroscopic imaging protocol optimized for D-2HG. The acquired D-2HG maps with a voxel size of 5.2 × 5.2 × 12 mm were upsampled to a voxel size of 1.7 × 1.7 × 3 mm using a super-resolution method that combined weighted total variation, feature-based nonlocal means, and high-spatial-resolution anatomic imaging priors. Validation with simulated healthy and patient data and phantom measurements was also performed. The Mann-Whitney
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.